Engineering myeloid cells for cancer immunotherapy
Authors:
- 3 July 2025
- journal article
- Published by Elsevier in Cancer Cell
- Vol. 43 (9) , 1593-1597
Abstract
No abstract availableKeywords
Funding Information
- Leukemia and Lymphoma Society of Canada
- Leukemia and Lymphoma Society
- Massachusetts Institute of Technology Koch Institute for Integrative Cancer Research (P30-CA14051)
- Parker Institute for Cancer Immunotherapy
- National Cancer Institute
This publication has 15 references indexed in Scilit:
- Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical modelsNature Communications, 2025
- Silencing of SIRPα enhances the antitumor efficacy of CAR-M in solid tumorsCellular & Molecular Immunology, 2024
- Activating innate immune responses repolarizes hPSC-derived CAR macrophages to improve anti-tumor activityCell Stem Cell, 2024
- Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancerCell Stem Cell, 2024
- In vivo human T cell engineering with enveloped delivery vehiclesNature Biotechnology, 2024
- Metabolic Reprogramming via ACOD1 depletion enhances function of human induced pluripotent stem cell-derived CAR-macrophages in solid tumorsNature Communications, 2023
- Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHLNature, 2022
- In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivoNature Communications, 2020
- CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemiaNature Biomedical Engineering, 2020
- Human chimeric antigen receptor macrophages for cancer immunotherapyNature Biotechnology, 2020